New FDA Chief Kyle Diamantas Faces Criticism Over Lack of Drug Experience

Senate Health Committee Chairman Bill Cassidy has criticized the new acting FDA commissioner, Kyle Diamantas, for lacking necessary experience in drug and medical device regulation. This scrutiny comes as the administration navigates complex regulatory decisions regarding public health and pharmaceutical safety. The appointment highlights ongoing debates over the qualifications required for top federal health officials.